BioSculpture Inc. New Technology for Obesity and Type 2 Diabetes

© 2020 All Rights Reserved.

CEO of BioSculpture Technology Inc., Robert L. Cucin M.D. on their company’s new technology that addresses Obesity and Type 2 Diabetes.

BioScultpture Technology has a game-changing technology which can do for obesity management and the treatment of Type 2 Diabetes what laser did for vision correction. The company’s earliest patent created the power system liposuction market, which grew to be half a billion dollars a year. Three things are unique about BioSculpture Technology:
  • the product itself, which allows physicians to remove the deep fat inside the abdomen that causes type 2 Diabetes.
  • the offering, which allows anybody to purchase the stock, not just wealthy investors and funds.
  • the regulatory pathway uses the company’s device as a predicate.

Medical devices and treatments

BioSculpture is bringing to the market two electronic devices for the bariatric treatment and one for the liposuction market:
  •  the revolutionary EVL® device for the bariatric and the liposuction markets;
  • Airbrush Liposculptor IIE, a sleek electrical version of the pneumatic Airbrush® Liposculptor II currently selling;
  • Airbrush® Liposculptor III, a next generation version of devices manufactured under licenses of their earliest tissue aspiration patent.

The Sky is the Limit

The size of this market is enormous and it’s virtually untouched. Expenditures with obesity related diseases grew 10% last year, surpassing $2.1 trillion. Consequently, a safer and effective alternative can expand the market well beyond the $1.5 billion spent last year, for only bariatric surgeries. Plans for the future plans include opening up branded treatment centers, which can cross sell liposuction and also ultra-fat autographed. The sky is the limit to to expand this market. For more information on BioSculpture Technology Inc. please fill out the form below.

Request Investor Info